This is a preview of subscription content, log in via an institution to check access.
Reference
Wisloff T, et al. Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation. PharmacoEconomics : 9 Apr 2014. Available from: URL: http://dx.doi.org/10.1007/s40273-014-0152-z
Rights and permissions
About this article
Cite this article
Which NOAC is best alternative to warfarin in AF stroke prevention?. PharmacoEcon Outcomes News 701, 8 (2014). https://doi.org/10.1007/s40274-014-1208-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1208-1